PubMed · 2006 · 12 citations · 0 references
Veterinary MedicineImmunologyInfectious DiseasesImmunology Of Infectious DiseasesInnate ImmunityVaccinologyHost-parasite Immune InteractionsImmune Response To VaccinationInnate Immune Responses To ParasitesInnate Immunity To ParasitesMacrophage BiologyMacrophage Responses To ParasitesAdjuvant MechanismsCellular Immune Response To ParasitesCytokine AdjuvantsImmunopathology Of LeishmaniasisLeishmaniasis PathogenesisMacrophage ImmunomodulationMacrophage Responses To LeishmaniaTreatment Of Leishmaniasis
Cutaneous leishmaniasis is a universal disease causing skin ulceration and deformity. A reliable vaccine remains to be a possible practical means of control. The amastigotes multiply intracellulary in macrophages provoking a cell-mediated type of immune response. IL-12 is the central cytokine of CMI. It is produced by sensitized macrophages, stimulates both Th1 and NK cells to secrete IFN-gamma which in turn activates the intracellular killing of Leishmania in macrophages via increased oxygen radicals. This work aimed mainly at studying the adjuvant effect of IL-12 on autoclaved L. major (ALM) vaccine, compared to that of BCG in L. major infection. The material included five groups of Swiss albino mice; the test group infected after receiving ALM+IL-12, a non-infected control group, and three other control groups infected after receiving ALM+BCG, IL-12 alone and BCG alone L. major was cultured to provide promastigotes for vaccine and infection. The measured parameters included the lesion size, type and progress; the parasite density and the level of IFN-gamma in serum. The results showed that the best protection against challenge infection was obtained by ALM + IL-12 followed by ALM + BCG. The former is recommended for use as a vaccine with regards to its proved efficacy and known safety.